Investigational Drug Information for AKB-6548
✉ Email this page to a colleague
What is the drug development status for AKB-6548?
AKB-6548 is an investigational drug.
There have been 38 clinical trials for AKB-6548.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2017.
The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Anemia. The leading clinical trial sponsors are Akebia Therapeutics, Aerpio Therapeutics, and Mitsubishi Tanabe Pharma Corporation.
There are eighteen US patents protecting this investigational drug and one hundred and ninety-six international patents.
Summary for AKB-6548
| US Patents | 18 |
| International Patents | 196 |
| US Patent Applications | 71 |
| WIPO Patent Applications | 53 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 3 (2017-08-01) |
| Vendors | 43 |
Recent Clinical Trials for AKB-6548
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease | Akebia Therapeutics | Phase 3 |
| Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents | Akebia Therapeutics | Phase 3 |
| Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | Akebia Therapeutics Inc. | Phase 2 |
Clinical Trial Summary for AKB-6548
Top disease conditions for AKB-6548
Top clinical trial sponsors for AKB-6548
US Patents for AKB-6548
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AKB-6548 | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| AKB-6548 | ⤷ Try a Trial | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Akebia Therapeutics, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| AKB-6548 | ⤷ Try a Trial | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | Akebia Therapeutics, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| AKB-6548 | ⤷ Try a Trial | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Akebia Therapeutics, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| AKB-6548 | ⤷ Try a Trial | Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof | Crystal Pharmaceutical (Suzhou) Co., Ltd. (Suzhou, CN) | ⤷ Try a Trial |
| AKB-6548 | ⤷ Try a Trial | Prolyl hydroxylase inhibitors and methods of use | Akebia Therapeutics, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AKB-6548
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AKB-6548 | Australia | AU2017261372 | 2036-05-05 | ⤷ Try a Trial |
| AKB-6548 | Canada | CA3023278 | 2036-05-05 | ⤷ Try a Trial |
| AKB-6548 | China | CN107847398 | 2036-05-05 | ⤷ Try a Trial |
| AKB-6548 | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Try a Trial |
| AKB-6548 | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Try a Trial |
| AKB-6548 | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
